Brush up on clinical trials guidance as Aduhelm spurs questions
CMS appears set to require participation in a clinical trial for coverage of an expensive new Alzheimer’s drug, which promises to raise patient interest in such trials. Be prepared to field patient inquiries and take the opportunity to prepare for other clinical trial inquiries in your field.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.